This week, virtual care company Babylon Health permanently closed its U.S. operations and laid off 94 employees. The news came after the company's rescue merger fell apart — Babylon had planned to go private through a deal with Swiss digital therapeutics firm MindMaze and Babylon creditor AlbaCore Capital.
OmniAb, the antibody division of Ligand Pharmaceuticals, is set to go public through a SPAC merger that will infuse the business with up to $266 million. The deal comes as traditional IPOs have mostly ground to a halt due to uncertain market conditions, but Ligand is making a longer-term bet on growing demand for antibody drug discovery services.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Eleusis is developing a formulation of the psychedelic compound psilocybin that overcomes limitations of pill versions of the drug. Depression is Eleusis’s lead disease target but the biotech notes that its research has shown the potential to bring psychedelic drugs beyond psychiatry.
ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell therapy for chronic kidney disease. More than slowing the decline in organ function, ProKidney says its cell therapy offers the potential to reverse injury caused by the condition.
Talkspace’s COO Mark Hirschhorn is resigning after an internal review of his conduct. This comes just a week after the departure of its co-founders and CEO.
The startup is developing digital therapeutics that use cognitive behavioral therapy-based programs to address cardiometabolic conditions. It began trading on Nasdaq on Friday.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
With a goal of making precision medicine the standard of care at health systems, Sema4 struck a nearly $800 million deal with CM Life Sciences to go public. The company, which offers tools that combine genomic and clinical data to glean patient care insights, will get $500 million in cash proceeds to grow its business.
Digital therapeutics startup Pear Therapeutics struck a deal to go public through a blank-check acquisition that would value the company at $1.6B. But it still faces big challenges in selling its app-based treatments.
In Venrock’s annual survey of healthcare leaders, respondents expected most digital health startups that went public during the pandemic to see their valuations fall by the end of the year.
Medication adherence startup PillDrill is suing a digital health company UpHealth, claiming it lied about plans to acquire the startup as part of a broader SPAC deal.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
As it makes a big push to expand in the U.S., digital health startup Babylon struck a deal to go public through a SPAC merger. The deal would value the company at $4.2 billion.
After acquiring startup Doc.AI, Sharecare is going public through a merger with a Mnuchin-backed special purpose acquisition company. In a recent filing, the company disclosed it had received $50 million in backing from Anthem.
Digital health startup Better Therapeutics plans to go public through a SPAC merger that would value it at $187 million. The company is currently running a pivotal study to see if its app-based program could be used as a treatment for type 2 diabetes.
Digital health startup Sharecare plans to go public through a merger with a blank-check company created by Alan Mnuchin. The deal will value the company at $3.9 billion.
Consumer DNA testing company 23andMe plans to go public through a merger with a special-purpose acquisition company started by Virgin Group. As sales of DNA testing kits wane, how will 23andMe drum up new interest for its business?